Table 1.

Selectin-directed compounds developed for the treatment of inflammatory disorders

Target	Compound	Company	Status	Reference
Selectins	CY-1503	Cytel Corp	Preclinical	Kerr et al 2000
Selectins	BMS-190394	BMS	Preclinical	Birnbaum et al 1997
Selectins		Aventis	Preclinical	Marinier et al 2001
Selectins	OC-229648	Ontogen Kanebo	Preclinical
Selectins	efomycine M	none	Preclinical	Schön et al 2002
E-selectin	ESA-2	Novartis	Preclinical	Thomson et al 1993; Bantely and Ernst 2001; Hafezi-Moghadam et al 2001; Biedermann et al 2002
Selectins	OJ- R9188	Nippon Organon	Preclinical	Ikegami-Kuzuhara et al 2001
Selectins	TBC-1269	Texas Biotechnology Revotar	Phase I/II	Abraham et al 1999; Anaya-Prado et al 2002
E- and P-selectin	PS3	None	Preclinical	Yvin et al 2002
E- and P-selectin	EP-5C7	Protein Design Labs	Phase I	Berg et al 1995; Alon et al 1998
E- and L-selectin	EL-246	LygoCyte	Preclinical	Carraway et al 1998
E-selectin	CDP-850	Celltech	Phase II	Bhushan et al 2002
P-selectin	rhPSGL-1 Ig	Genetics Institute	Phase II	Khor et al 2000
L-selectin	LD201t1	WyethNeXStar	Preclinical	Hicke et al 1996